IconOVir Bio to Present Preclinical Data on Lead Candidate ICVB-1042 at SITC 2022
SAN DIEGO, CA., Oct. 5, 2022 – IconOVir Bio, Inc. (IconOVir), a preclinical-stage biotechnology company pioneering the next generation of oncolytic virus (OV) therapy to improve the treatment of patients with cancer, today announced that it will present preclinical data on ICVB-1042 in three poster presentations at the upcoming Annual Meeting of the Society for […]